BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 9700583)

  • 1. Meta-analysis of clodronate and breast cancer survival.
    Ha TC; Li H
    Br J Cancer; 2007 Jun; 96(12):1796-801. PubMed ID: 17325699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and consequences of bone metastases in lung cancer patients.
    Kuchuk M; Addison CL; Clemons M; Kuchuk I; Wheatley-Price P
    J Bone Oncol; 2013 Feb; 2(1):22-9. PubMed ID: 26909268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis.
    Lopez-Olivo MA; Shah NA; Pratt G; Risser JM; Symanski E; Suarez-Almazor ME
    Support Care Cancer; 2012 Nov; 20(11):2985-98. PubMed ID: 22956190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases.
    Polascik TJ
    Drug Des Devel Ther; 2009 Sep; 3():27-40. PubMed ID: 19920919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of hormone-refractory prostate cancer].
    Heidenreich A
    Urologe A; 2005 Dec; 44(12):1481-94; quiz 1495. PubMed ID: 16311709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment options for hormone-refractory prostate cancer].
    Heidenreich A; Ohlmann CH
    Urologe A; 2005 Nov; 44(11):1303-4, 1306-14. PubMed ID: 16237541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for the relief of pain secondary to bone metastases.
    Wong R; Wiffen PJ
    Cochrane Database Syst Rev; 2002; 2002(2):CD002068. PubMed ID: 12076438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant bone pain: pathophysiology and treatments.
    Ripamonti C; Fulfaro F
    Curr Rev Pain; 2000; 4(3):187-96. PubMed ID: 10998732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
    Machado M; Cruz LS; Tannus G; Fonseca M
    Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
    Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R
    J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
    Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer.
    Strang P; Nilsson S; Brändstedt S; Sehlin J; Borghede G; Varenhorst E; Bandman U; Borck L; Englund G; Selin L
    Anticancer Res; 1997; 17(6D):4717-21. PubMed ID: 9494595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
    Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
    J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.